Freenome

At Freenome, we’re developing next-generation blood tests for early cancer detection, powered by our multiomics platform

Moving early cancer detection forward, for all There is no blueprint for putting an end to cancer That’s why Freenomers push to achieve what is now possible to discover the body’s earliest warning signs of cancer, and develop accessible tests to detect cancer in its earliest, most treatable stages

Using a standard blood draw for early cancer detection We are developing early cancer detection blood tests tailored to different types of cancer by looking at biomarkers from both tumor and non-tumor-derived sources to detect the body’s earliest warning signs of cancer

Our blood tests are being developed using our multiomics platform, which combines our deep expertise in molecular biology and machine learning to identify cancer-associated patterns among billions of circulating biomarkers from tumor and non-tumor-derived sources We also partner with health systems to integrate actionable insights and create a feedback loop between care and science

Sign up to receive the latest news on clinical trials, publications, and more

We respect your privacy